
Opinion|Videos|July 2, 2024
AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety
The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.
Advertisement
Episodes in this series

- What are the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations on the treatment of patients with HE?
Vilstrup et al 2014 ,EASL 2022 - managing covert HE
- managing overt HE
- In primary care we are somewhat familiar with rifaximin. For patients with HE, can the primary care clinician prescribe it or does the hepatologist/gastroenterologist have to prescribe it?
- What are some reasons why rifaximin is under prescribed by PCP’s?
- What are strategies to help increase uptake?
- What do we know about treatment adherence of rifaximin?
- What data do we have on the safety and efficacy of rifaximin in HE?
Yu et al 2021 ,Zacharias et al 2023 - Alone and as combination therapy
- How do you handle payer approval, what is required?
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

